PUBLISHER: IMARC | PRODUCT CODE: 1801174
PUBLISHER: IMARC | PRODUCT CODE: 1801174
The global acne drugs market size reached USD 7.2 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 11.2 Billion by 2033, exhibiting a growth rate (CAGR) of 4.9% during 2025-2033. The market is primarily driven by the rising prevalence of acne among adults and adolescents, the increasing awareness and emphasis on skincare, the ongoing advancements in pharmaceutical R&D for innovative treatments, and the emerging social media influence.
Increasing Prevalence of Acne
The increasing prevalence of acne among adults and adolescents across the globe is primarily driving the acne drug market statistics. Moreover, the rising hormonal changes during puberty, high stress levels of individuals, and several lifestyle factors, including poor diet and inadequate skincare routines are anticipated to propel the market growth forward. Besides this, the extensive research and development efforts by the major pharmaceutical companies for creative innovative, accessible, and reliable acne medications are also positively influencing the market expansion. For instance, the data published by ClickPharmacy reported that 34% of United Kingdom adults have suffered from acne at some point in their lives. The same source mentioned that 6.1% of men are currently suffering from acne when compared to 2.5% of women. Also, the article published by Sahel Medical Journal mentioned that the prevalence of acne vulgaris in South Nigeria was 37.3% with a higher prevalence in females (37.6%) than in males (36.7%). On account of this, numerous key players are focusing on the introduction of adequate acne treatment solutions to reach out to a large patient base suffering from acne. For example, in June 2023, Sun Pharmaceutical Industries Ltd., received approval from Health Canada, the country's health regulator, for its WINLEVI cream, used in treating acne and acne scars.
Growing Awareness and Emphasis on Skincare
The growing emphasis and awareness regarding skincare and personal appearance is augmenting the acne drugs market growth. Moreover, the inflating expenditures by individuals, especially in developing economies, on skincare products and treatments that aid in achieving clear and blemish-free skin are also catalyzing the global market. Besides this, the increasing influence of social media and celebrity endorsements and the escalating demand for therapies that enhance the appearance of the skin are also positively influencing the market growth. For example, Galderma launched a new digital campaign. "Me Being Me" for topical acne treatment with Aklief (trifarotene) Cream. The company educated patients about Aklief, which is the first new retinoid molecule to gain approval for acne vulgaris in more than 20 years. In addition to this, Stryke Club introduced retinoid acne treatment with its Knockout Adapalene Gel that prevents pimples, blackheads, whiteheads, and clogged pores. Moreover, in September 2023, Marksans Pharma completed the acquisition of Teva Pharmaceuticals in India to continue providing an uninterrupted supply of Teva's important medicines to customers and patients.
Advancements in Pharmaceutical Research and Development
The continuous advancements in pharmaceutical research and development for creating innovative and more efficient formulations for acne treatment are positively influencing the market growth. In addition to this, the inflating investments by regulatory authorities in the study and introduction of the latest and improved acne drugs are also propelling the market expansion. Moreover, the growing popularity of improved drug delivery systems, the discovery of novel active ingredients, and the widespread adoption of combination therapies that target various aspects of acne are further catalyzing the acne drug market revenue. For instance, Galderma announced the U.S. launch of its "Twyneo" Cream, 0.1%/3% at the American Academy of Dermatology (AAD) Annual Meeting in Boston, Massachusetts. TWYNEO Cream is the first and only 0.1% tretinoin and 3% benzoyl peroxide (BPO) 2-in-1 combination proven to rapidly treat moderate to severe facial acne. Moreover, in May 2023, Bausch Health Companies Inc. announced that the U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) for investigational IDP-126 (clindamycin 1.2%/adapalene 0.15%/benzoyl peroxide 3.1%) Gel with a Prescription Drug User Fee Act (PDUFA).
Global Acne Drugs Market Segmentation
In the comedonal segment, the high prevalence of non-inflammatory acne cases, increasing accessibility to over-the-counter remedies, and the desire for clear, blemish-free skin are primarily driving the market growth. Besides this, the escalating demand for potent anti-inflammatory agents and the ongoing research activities for the development of effective acne treatment solutions are catalyzing the market in the inflammatory segment. Moreover, the rising need for prescription-based medications, the growing popularity of advanced therapies, the elevating requirement for post-procedure skincare, and the emerging trend of cosmetic surgeries, are propelling the expansion of the acne drugs market in the cystic and postsurgical/wound segments.
Retinoids dominate the market
The rising awareness towards the utilization of retinoids in acne treatment is majorly fueling the market growth in this segment. Besides this, the extensive product need among healthcare professionals and individuals for effective acne treatment, owing to their ability to regulate skin cell turnover, prevent the formation of comedones (blackheads and whiteheads), and reduce inflammation, is augmenting the market growth further.
The easy accessibility of over-the-counter (OTC) drugs and the increasing individual interest in self-care solutions are bolstering the growth of the acne drug market in this segment. Besides this, the rising need for quick remedies, which are readily available in supermarkets, pharmacies, and online outlets, among consumers for common skin concerns is positively influencing the demand for acne drugs globally. For instance, Sun Pharma teamed up with dermatologist Dr. Sandra Lee on the TLC network to spotlight the role of hormones in the underlying cause of skin acne through a campaign called 'AH-ha! It's Acne Hormones'. The campaign featured a diverse group of people of age, gender, and ethnicity and guided the population of the U.S. to follow an effective skin care regimen that may involve OTC products.
Topical holds the largest share in the market
The convenience of topical treatments plays a significant role in the acne drug market outlook, as these products are easy to apply directly to affected areas, making them a preferred choice for several individuals seeking localized acne management. Besides this, the ongoing research and development efforts in the pharmaceutical sector for the introduction of innovative formulations with fewer side effects and better outcomes are also catalyzing the market growth in this segment. For instance, the U.S. FDA approved Opzelura (ruxolitinib), a cream for treating mild to moderate atopic dermatitis in patients aged 12 years and older who are not able to use other treatments or fail to get enough symptom relief from other therapies.
North America exhibits a clear dominance, accounting for the largest acne drugs market share
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.
North America represented the largest segment for the acne drugs market, owing to its advanced healthcare infrastructure and the inflating expenditure capacities of individuals. Besides this, the high prevalence of acne among adolescents and adults, the development of state-of-the-art medical technology, and the easy accessibility to medical professionals and dermatologists are also catalyzing the growth of the market in this region. In addition to this, the rising individual inclination towards maintaining their appearance and beauty is positively influencing the market growth. For instance, in Canada, Bausch Health's subsidiary Ortho Dermatologics announced positive topline data from its second Phase III trial for IDP-126, a three-compound combination gel tested in 193 patients with acne vulgaris. This clinical trial showed reductions in both inflammatory and non-inflammatory lesions at week 12 in both problems. IDP-126 combines adapalene, retinol, and anti-microbial benzoyl peroxide.
The competitive landscape of the global acne drugs market is characterized by a diverse array of pharmaceutical and healthcare companies striving to offer innovative and effective solutions for acne treatment. While specific players are not mentioned here due to the user's request, it's important to note that the market fosters competition through research and development, strategic collaborations, and product diversification. Companies within this space are continually investing in R&D to formulate new medications and therapies that target various types of acne, ranging from mild to severe cases. Partnerships with dermatologists and skincare experts help in endorsing their products, adding credibility and market reach. Furthermore, marketing strategies, including digital marketing and social media, play a pivotal role in promoting their products and educating consumers about effective acne management. The competitive landscape emphasizes the importance of quality, safety, and innovation in addressing the diverse needs of individuals seeking acne treatments, ultimately benefiting consumers with a wider range of options and improved solutions.
The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided. Some of the major market players in the Acne Drugs industry include: